Fang Donghong, Wan Xuesi, Deng Wanping, Guan Hongyu, Ke Weijian, Xiao Haipeng, Li Yanbing
Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, P.R. China.
Exp Ther Med. 2012 Nov;4(5):871-876. doi: 10.3892/etm.2012.680. Epub 2012 Aug 23.
Fufang Xue Shuan Tong (FXST) capsules, a traditional Chinese medicine, have been used to treat diabetic nephropathy for many years. FXST has been shown to attenuate elevated levels of oxidative stress in the retina of diabetic rats. However, whether FXST protects kidneys through the same mechanism(s) remains unclear. In this study, diabetes was induced in rats by administration of a high-fat diet and low-dose streptozotocin. Rats were administered low (450 mg/kg/day), middle (900 mg/kg/day) or high (1800 mg/kg/day) doses of FXST orally for 3 months. Another group was administered 50 mg/kg/day orally for the same period. The results indicated that all doses of FXST reduced urinary protein excretion and creatinine clearance and ameliorated the diabetic nephropathy-related mesangial matrix expansion. However, only middle and high doses of FXST prevented glomerular hypertrophy in diabetic rats, and the high dose showed the greatest inhibitory effect with regard to mesangial matrix expansion. Furthermore, superoxide dismutase activities were significantly elevated, whereas malondialdehyde levels were significantly reduced in the renal cortex following FXST treatment. The kidney-protective role of FXST is not inferior to that of captopril, one of the most commonly used drugs for the treatment of diabetic nephropathy. In conclusion, FXST retards the progression of diabetic nephropathy, while high-dose FXST shows the most prominent effect in counteracting the pathological changes of diabetic nephropathy. The renoprotective action of FXST is induced by the reduction of oxidative stress in diabetic nephropathy.
复方血栓通（FXST）胶囊是一种传统中药，多年来一直用于治疗糖尿病肾病。已证明FXST可减轻糖尿病大鼠视网膜中氧化应激水平的升高。然而，FXST是否通过相同机制保护肾脏仍不清楚。在本研究中，通过给予高脂饮食和低剂量链脲佐菌素诱导大鼠患糖尿病。大鼠口服低剂量（450毫克/千克/天）、中剂量（900毫克/千克/天）或高剂量（1800毫克/千克/天）的FXST，持续3个月。另一组在同一时期口服50毫克/千克/天。结果表明，所有剂量的FXST均降低了尿蛋白排泄和肌酐清除率，并改善了糖尿病肾病相关的系膜基质扩张。然而，只有中剂量和高剂量的FXST可预防糖尿病大鼠的肾小球肥大，且高剂量在系膜基质扩张方面显示出最大的抑制作用。此外，FXST治疗后肾皮质中的超氧化物歧化酶活性显著升高，而丙二醛水平显著降低。FXST的肾脏保护作用不低于卡托普利，卡托普利是治疗糖尿病肾病最常用的药物之一。总之，FXST可延缓糖尿病肾病的进展，而高剂量的FXST在对抗糖尿病肾病的病理变化方面显示出最显著的效果。FXST的肾脏保护作用是通过降低糖尿病肾病中的氧化应激诱导产生的。
